494222-22-9

Upstream product

• 626-15-3 1,3-bis-(bromomethyl)benzene 
• 1365392-14-8 methyl 4-[(2-{(2R)-2-[(1E,3S)-3-hydroxy-4-{3-[(2,2,2-trifluoroethoxy)methyl]phenyl}-1-buten-1-yl]-5-oxo-1-pyrrolidinyl}ethyl)thio]butanoate 
• 1355026-91-3 dimethyl [3-[3-(2,2,2-trifluoroethoxymethyl)phenyl]-2-oxopropane]phosphonate 
• 1365392-91-1 methyl {3-[(2,2,2-trifluoroethoxy)methyl]phenyl}acetate 
• 492471-47-3 9-oxo-12-formyl-13,14,15,16,17,18,19,20-octanor-5-thia-8-azaprostanoic acid methyl ester 
• 492471-45-1 9-oxo-13-hydroxy-14,15,16,17,18,19,20-heptanor-5-thia-8-azaprostanoic acid methyl ester 

Relevant academic research and scientific papers

Discovery of orally available 8-aza-5-thiaProstaglandin E1 analogs as highly selective EP4 agonists

Analogs 8-aza-16-aryl prostaglandin E1 (PGE1) and 8-aza-5-thia-16-arylPGE1 were synthesized and evaluated with respect to their subtype receptor affinity and EP4 agonist activity for the purposes of identifying sub-type- selective EP

REMEDIES FOR DISEASES WITH BONE MASS LOSS HAVING EP sb 4 /sb AGONIST AS THE ACTIVE INGREDIENT

A pharmaceutical composition for topical administration for prevention and/or treatment of diseases associated with decrease in bone mass comprising an EP4 agonist as an active ingredient. An EP4 agonist, in which includes a compound